Peter Schafer
Chair, PROLIFIC Consortium Bristol Myers Squibb
Peter is the co-founder of PROLIFIC, where he’s leading efforts to develop the PROLIFIC Risk Score for patient stratification and early drug activity in pulmonary fibrosis. Previously, he was Scientific VP of Translational Medicine at Bristol Myers Squibb and held senior roles at Celgene, contributing to the development of apremilast (Otezla®), lenalidomide (Revlimid®), and pomalidomide (Pomalyst®). He co-chairs the Lupus Nexus Steering Committee and leads the Lupus Nephritis Biomarker Working Group. Peter holds a Ph.D. from Northwestern University and has authored over 100 publications and co-invented more than 80 patents.
Seminars
Thursday 21st August 2025
Collaborative Acceleration: PROLIFIC Consortium Update on Advancing PF Research Through Real-World Data & Biomarker Integration
2:00 pm
- Explore how the PROLIFIC Consortium is leveraging longitudinal clinical data and biosamples across diverse care settings to refine our understanding of pulmonary fibrosis progression and treatment outcomes
- Get the latest updates on multi-center efforts to identify, validate, and implement molecular and imaging biomarkers that can predict progression, inform trial design, and personalize care
- Understand how this NIH-funded initiative is creating a robust framework to support open science, harmonized data collection, and future clinical trials by bringing together academic centers, biobanks, and industry partners
